Home / Ingredients / H / Hydroquinone
Hydroquinone
Hydroquinone blocks pigment production and is the most effective topical treatment for melasma and dark spots. In the UK it's banned from cosmetics and available only on prescription, because misuse can cause irritation and, rarely, a blue-black discolouration called ochronosis. Products sold without a prescription that contain it are illegal.
What it does, and how sure we are
| Use | What studies found | Strength | Evidence |
|---|---|---|---|
| Melasma | A 4% hydroquinone cream improved melasma more than placebo in a randomised trial.1 | 4% | Strong |
| Combination cream | Hydroquinone combined with tretinoin and a steroid (the Kligman formula) depigmented skin more effectively than each alone.2 | 5% | Moderate |
| Ochronosis | Long-term use, especially of high-strength or unlicensed products, can cause exogenous ochronosis, a blue-black darkening that's hard to treat.3 | – | Moderate |
Strong: several good trials agree. Moderate: at least one solid trial plus supporting work. Limited: small or company-run trials, or mostly lab studies. Very limited: little beyond lab work or claims.
How to use it
- Only under medical supervision in the UK, usually in courses of a few months with breaks.
- Use strict daily sun protection.
What to use it with
Side effects and safety
Irritation and redness are common. Ochronosis is rare but serious and linked to prolonged or high-strength use. Avoid unlicensed imported "lightening" creams, which may also contain mercury or strong steroids.
Myths
“Hydroquinone is banned because it causes cancer.”
The UK and EU restrict it to prescription use mainly because of misuse and ochronosis risk; cancer concerns come from animal studies at high doses.
Questions
What can I use instead without a prescription?
Azelaic acid, tranexamic acid, niacinamide, alpha arbutin and daily sunscreen.
References
- Haddad AL, Matos LF, Brunstein F, et al. A clinical, prospective, randomized, double-blind trial comparing skin whitening complex with hydroquinone vs. placebo in the treatment of melasma. Int J Dermatol. 2003;42(2):153-6. PubMed
- Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol. 1975;111(1):40-8. PubMed
- Levin CY, Maibach H. Exogenous ochronosis. An update on clinical features, causative agents and treatment options. Am J Clin Dermatol. 2001;2(4):213-7. PubMed